Compare Crispr Therapeutics AG (CRSP) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Prudential Financial Inc — how do they compare? Crispr Therapeutics AG trades at $53.81 (market cap $5.23B), while Prudential Financial Inc trades at $122.34 (market cap $42.20B). The key difference: Prudential Financial Inc is far larger — about 8.1× Crispr Therapeutics AG's market cap, and Prudential Financial Inc pays a 4.58% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | PRU | |
|---|---|---|
Market Cap | $5.23B | $42.20B |
Sector | Health | Financials |
52-Week High | $76.78 | $123.93 |
52-Week Low | $44.34 | $92.00 |
Enterprise Value | $3.65B | $70.98B |
Dividend Yield | — | 4.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
Prudential Financial (PRU) trades at $122.11, up 0.68% today, with a bullish technical signal and strong Q2 2026 earnings beats. The stock shows solid fundamentals with a P/E of 11.09, ROE of 12.46%, and a $1.40 quarterly dividend. Recent news highlights strategic growth in wealth management and PGIM strength, though China tax concerns caused volatility.
Outlook is cautiously positive given earnings momentum and capital-light strategy, but risks include regulatory uncertainty in China and mixed analyst sentiment with 67.57% hold ratings. The consensus price target of $113.11 suggests limited upside from current levels, requiring monitoring of international operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
